“A Randomized, Double-Blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis”. SKIN The Journal of Cutaneous Medicine 5, no. 6 (November 5, 2021): s94. Accessed July 3, 2025. https://skin.dermsquared.com/skin/article/view/1445.